Results of a phase II trial of the PARP inhibitor olaparib, presented at the meeting of the Society of Gynecologic Oncology, showed that maintenance therapy with olaparib significantly improved PFS in ovarian cancer patients.
Patients randomized to olaparib had a 60% improvement in the exploratory endpoint of time to first subsequent therapy or death (TFST) as compared with placebo-treated patients, according to Ursula Matulonis, MD,
of the Dana-Farber Cancer Institute in Boston, and colleagues. Time to second subsequent therapy (TSST) also was significantly prolonged in the olaparib group.
The significant advantage applied to the overall analysis and to subgroup analyses by BRCA mutation status, they reported here at the Society of Gynecologic Oncology meeting.
"In this phase II trial, olaparib maintenance monotherapy led to clinical benefits that persisted beyond the first progression by RECIST criteria," Matulonis said. "Statistically significant improvements in progression-free survival, time to first subsequent therapy, and time to second subsequent therapy, in favor of olaparib, were observed in the overall patient population and in both BRCA-mutant and wild-type subgroups."
"The benefits of olaparib therapy were greatest in the BRCA-mutant subgroup," she added.
Read the complete story here:
http://bit.ly/1guLYjv Source: Medpage Today